Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-12-19

FDA Approved: BYLVAY — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for BYLVAY (odevixibat) from Ipsen Biopharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BYLVAY (odevixibat)

Snippet

SUPPL AP for BYLVAY (ODEVIXIBAT)